Skip to main content

Find a trial

Find a trial

Trial status
Trial Phase
Trial type
96 clinical trials grid list download
  • Title Organ Phase Statut Major inclusion criteria Contact
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1 Ahmad Hussein Awada
  • 2129 - TREAT ctDNA Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) Breast phase 3 Open Michail Ignatiadis
  • AL-TNBC-01 - TENACITY A Phase 2, Multicenter, Open-label, Single arm Study of AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer Breast phase 2 Closed Philippe Aftimos
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1 Philippe Aftimos
  • APHINITY A randomised multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. Breast Closed Non metastatic, operable HER2+ carcinoma of the breast Martine Piccart
  • APPALACHES A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cancer (APPALACHES) (PILOT039) Breast phase 2 Closed Stage II or stage III, early invasive breast cancer. ER+/HER2- Michail Ignatiadis
  • Ascent An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments Breast phase 3 Closed 3rd line metastatic Philippe Aftimos
  • ASCENT-04 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 Breast phase 3 Open Evandro De Azambuja
  • AURORA BIG 14-01 AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer Breast phase 3 Open after one line, biopsy Philippe Aftimos
  • B PRECISE 01 Open-label, multicentre, phase Ib dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab +/- fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy Breast phase 1/1b Closed HER+. Advanced or metastatic with PIK3CA mutation Philippe Aftimos
  • BAY 88-8223 / 16996 A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride Multiple phase 4 Closed Subject was previously enrolled in a selected company-sponsored feeder trial, and has received at least 1 dose of radium-223 dichloride or placebo in the feeder trial. Géraldine Gebhart
  • BAY 88-8223 / 17096 A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases Breast phase 2 Closed *HER negative hormone receptor positive breast cancer
    * received at least one line of hormonal therapy in the metastatic setting
    *eligible for exemestane and everolimus
    * experienced no more than 2 skeletal related event (SRE)
    Géraldine Gebhart
  • BSMO 2014 01 A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negative breast cancer Breast phase 2 Closed TNBC Daphné t'Kint de Roodenbeke
  • CA209358 Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors Multiple phase 1/2 Closed ECOG 0 or 1 Ahmad Hussein Awada